Emeramide (N,N′-bis(2-mercaptoethyl)isophthalamide) is an investigational compound currently under FDA review as a treatment for mercury poisoning. The publications below are peer-reviewed scientific studies. They do not constitute FDA-approved claims or indications.
These studies relate to Emeramide’s development for mercury poisoning, the indication currently under FDA review.
Pilot Study Results: Emeramide (NBMI) in Mercury-Exposed Gold Miners in Zaruma Ecuador
Discover results from a pilot study of NBMI (Emeramide) in mercury-exposed gold miners in Zaruma, Ecuador. The 300 mg/day group showed significant reduction in physical fatigue and promising improvements in symptoms and urinary mercury levels despite ongoing exposure.
Emeramide (N,N′-bis(2-mercaptoethyl)isophthalamide) is an investigational compound currently under FDA review as a treatment for mercury poisoning. The publications below are peer-reviewed scientific studies. They do not constitute FDA-approved claims or indications. These studies explore Emeramide’s interaction with metals other than mercury or its potential effects in various preclinical disease models.
Disclaimer: These publications reflect early preclinical research only. Emeramide is not approved and is not under FDA review for any indication involving other metals or these conditions. Results from these studies should not be interpreted as evidence of safety or efficacy in humans for any use beyond mercury poisoning.
Disclaimer: These publications reflect early preclinical research only. Emeramide is not approved and is not under FDA review for any indication involving other metals or these conditions. Results from these studies should not be interpreted as evidence of safety or efficacy in humans for any use beyond mercury poisoning.